Combining KLF9 expression restoration with PI3K/Akt pathway inhibition may yield synergistic therapeutic effects to counteract pathway dysregulation, while its biomarker potential warrants validation in PI3K/Akt-driven tumor subtypes. This evidence concerns the gene AKT1 and neoplasm.